
    
      Patients will undergo screening assessment to determine the eligibility for study
      participation and will be randomized in 1:1 ratio to receive Teriparatide 20 Î¼g or placebo
      subcutaneous once daily for 12 weeks.

      All patients will receive supplements of 1000 mg/day of elemental calcium and 20,000 IU/week
      of vitamin D2.

      Patients will be scheduled to clinic visit for radiographic and clinical assessment at 2,
      6,12 and 24 weeks postoperatively. Each participant will be in the study for 6 months in
      total.
    
  